Boro Dropulic

发表

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Alexander Popov, Olga Molostova, Larisa Shelikhova, 2019 .

In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication.

Boro Dropulic, L. Humeau, Brian M Davis, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Gene transfer in humans using a conditionally replicating lentiviral vector

John R. Mascola, Bruce L. Levine, Frederic D. Bushman, 2006, Proceedings of the National Academy of Sciences.

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

Yang Feng, Boro Dropulic, Marianna Sabatino, 2017, Nature Medicine.

Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome.

Boro Dropulic, C. June, Carl H June, 2006, Human gene therapy.

Antisense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance

Boro Dropulic, John Rossi, J. Rossi, 2004, Journal of Virology.

Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection

Robert Kammerer, Boro Dropulic, Wolfgang Zimmermann, 2009, Molecular Cancer Therapeutics.

Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.

Richard Carroll, Bruce L Levine, Boro Dropulic, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Generation of a packaging cell line for prolonged large‐scale production of high‐titer HIV‐1‐based lentiviral vector

Brian Davis, Boro Dropulic, V. Slepushkin, 2005, The journal of gene medicine.

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Parameswaran Hari, Mehdi Hamadani, Dina Schneider, 2018, Blood.

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

Ying Xiong, Andrew Kaiser, Dina Schneider, 2017, Journal of Immunotherapy for Cancer.